Page 1 of 72
NURS 5334 ADVANCED PHARMACOLOGY EXAM PREP 2026 QUESTIONS
WITH VERIFIED ANSWERS DETAILED RATIONALES GRADED A+
Part I: Pharmacokinetics & Pharmacodynamics (Questions 1–30)
1. The study of the impact of the body on drugs, including how much of an
administered dose reaches its site of action, is defined as which of the following?
A. Pharmacodynamics
B. Pharmacokinetics
C. Pharmacotherapeutics
D. Pharmacogenomics
Rationale: Pharmacokinetics is the study of the impact of the body on drugs,
encompassing how much of an administered dose reaches its sites of action. The
four major pharmacokinetic processes are absorption, distribution, metabolism,
and excretion (ADME).
2. Which of the following represents the four major pharmacokinetic processes?
A. Drug administration, distribution, metabolism, and elimination
B. Drug absorption, distribution, metabolism, and excretion
C. Drug absorption, transportation, metabolism, and elimination
D. Drug administration, transportation, metabolism, and excretion
Rationale: The four major pharmacokinetic processes are absorption (movement
from administration site into blood), distribution (movement from blood to
tissues), metabolism (biotransformation), and excretion (removal from the body).
3. Pharmacodynamics is best defined as which of the following?
A. The impact of the body on drugs
B. What the drug does to the body, including receptor effects
1|Page
,Page 2 of 72
C. The movement of drugs across membranes
D. The genetic influence on drug response
Rationale: Pharmacodynamics describes the impact of drugs on the body,
involving drug-receptor interactions and the dose-response relationship.
Pharmacokinetics, by contrast, describes the body's effect on the drug.
4. A pharmacokinetic parameter that describes the fraction of an administered
dose of a drug that reaches the systemic circulation in an unchanged form is
known as which of the following?
A. Volume of distribution
B. Bioavailability
C. Clearance
D. Half-life
Rationale: Bioavailability measures the rate and extent to which an active drug
ingredient is absorbed and becomes available at the site of action or in systemic
circulation.
5. A drug with a high first-pass effect, such as nitroglycerin, is often given by which
route to bypass the liver?
A. Orally in high doses only
B. Rectally only
C. Sublingually or transdermally
D. Never
Rationale: A high first-pass effect means a large portion of an orally administered
drug is metabolized by the liver before reaching systemic circulation. Sublingual
and transdermal routes bypass the portal circulation and avoid this effect.
6. A drug reaches steady-state concentration in approximately how many half-
lives?
A. 1–2
B. 4–5
2|Page
,Page 3 of 72
C. 8–10
D. 12–15
Rationale: Steady-state concentrations are typically achieved after approximately
4–5 half-lives of regular dosing, when the rate of drug input equals the rate of
drug elimination.
7. Which pharmacokinetic parameter relates the amount of drug in the body to its
plasma concentration?
A. Clearance
B. Volume of distribution (Vd)
C. Bioavailability
D. Half-life
Rationale: Volume of distribution (Vd) is a theoretical volume that relates the
amount of drug in the body to its plasma concentration. It helps determine the
loading dose.
8. A patient with chronic kidney disease (Stage 4) is prescribed a medication that
is primarily renally excreted. The APRN should anticipate which of the following?
A. An increased dose is required
B. A decreased dose is required due to reduced clearance
C. No dose adjustment is needed
D. The drug will have a shorter half-life
Rationale: Renal impairment reduces the clearance of renally excreted drugs,
prolonging their half-life and increasing the risk of accumulation and toxicity. Dose
reduction is often necessary.
9. What is the primary determinant of a maintenance dose for a drug?
A. The drug's cost
B. Clearance and the desired steady-state concentration
C. The drug's color
D. The patient's height
3|Page
, Page 4 of 72
Rationale: Maintenance dosing is based on clearance (the rate of drug
elimination) and the target steady-state concentration.
10. Which of the following best describes the concept of a loading dose?
A. A dose given only when symptoms worsen
B. An initial higher dose used to rapidly achieve therapeutic drug concentrations
C. A maintenance dose given daily
D. A dose reduced for renal impairment
Rationale: Loading doses rapidly achieve therapeutic levels when the time to
steady state would otherwise be prolonged.
11. Which of the following statements about a drug with a narrow therapeutic
index is most accurate?
A. It has a wide margin of safety
B. It requires careful monitoring of serum levels to avoid toxicity
C. It never requires dose adjustment
D. It is always safe in pregnancy
Rationale: A narrow therapeutic index means the toxic and effective ranges are
close, requiring careful monitoring of drug levels (e.g., digoxin, lithium, warfarin).
12. Which of the following is an example of a drug that requires therapeutic drug
monitoring due to a narrow therapeutic index?
A. Amoxicillin
B. Digoxin
C. Acetaminophen
D. Vitamin C
Rationale: Digoxin has a narrow therapeutic index and requires serum level
monitoring to avoid toxicity.
13. Which of the following best describes the placebo effect?
A. A drug's direct pharmacologic effect
B. A therapeutic response produced by expectation or belief rather than the
4|Page
NURS 5334 ADVANCED PHARMACOLOGY EXAM PREP 2026 QUESTIONS
WITH VERIFIED ANSWERS DETAILED RATIONALES GRADED A+
Part I: Pharmacokinetics & Pharmacodynamics (Questions 1–30)
1. The study of the impact of the body on drugs, including how much of an
administered dose reaches its site of action, is defined as which of the following?
A. Pharmacodynamics
B. Pharmacokinetics
C. Pharmacotherapeutics
D. Pharmacogenomics
Rationale: Pharmacokinetics is the study of the impact of the body on drugs,
encompassing how much of an administered dose reaches its sites of action. The
four major pharmacokinetic processes are absorption, distribution, metabolism,
and excretion (ADME).
2. Which of the following represents the four major pharmacokinetic processes?
A. Drug administration, distribution, metabolism, and elimination
B. Drug absorption, distribution, metabolism, and excretion
C. Drug absorption, transportation, metabolism, and elimination
D. Drug administration, transportation, metabolism, and excretion
Rationale: The four major pharmacokinetic processes are absorption (movement
from administration site into blood), distribution (movement from blood to
tissues), metabolism (biotransformation), and excretion (removal from the body).
3. Pharmacodynamics is best defined as which of the following?
A. The impact of the body on drugs
B. What the drug does to the body, including receptor effects
1|Page
,Page 2 of 72
C. The movement of drugs across membranes
D. The genetic influence on drug response
Rationale: Pharmacodynamics describes the impact of drugs on the body,
involving drug-receptor interactions and the dose-response relationship.
Pharmacokinetics, by contrast, describes the body's effect on the drug.
4. A pharmacokinetic parameter that describes the fraction of an administered
dose of a drug that reaches the systemic circulation in an unchanged form is
known as which of the following?
A. Volume of distribution
B. Bioavailability
C. Clearance
D. Half-life
Rationale: Bioavailability measures the rate and extent to which an active drug
ingredient is absorbed and becomes available at the site of action or in systemic
circulation.
5. A drug with a high first-pass effect, such as nitroglycerin, is often given by which
route to bypass the liver?
A. Orally in high doses only
B. Rectally only
C. Sublingually or transdermally
D. Never
Rationale: A high first-pass effect means a large portion of an orally administered
drug is metabolized by the liver before reaching systemic circulation. Sublingual
and transdermal routes bypass the portal circulation and avoid this effect.
6. A drug reaches steady-state concentration in approximately how many half-
lives?
A. 1–2
B. 4–5
2|Page
,Page 3 of 72
C. 8–10
D. 12–15
Rationale: Steady-state concentrations are typically achieved after approximately
4–5 half-lives of regular dosing, when the rate of drug input equals the rate of
drug elimination.
7. Which pharmacokinetic parameter relates the amount of drug in the body to its
plasma concentration?
A. Clearance
B. Volume of distribution (Vd)
C. Bioavailability
D. Half-life
Rationale: Volume of distribution (Vd) is a theoretical volume that relates the
amount of drug in the body to its plasma concentration. It helps determine the
loading dose.
8. A patient with chronic kidney disease (Stage 4) is prescribed a medication that
is primarily renally excreted. The APRN should anticipate which of the following?
A. An increased dose is required
B. A decreased dose is required due to reduced clearance
C. No dose adjustment is needed
D. The drug will have a shorter half-life
Rationale: Renal impairment reduces the clearance of renally excreted drugs,
prolonging their half-life and increasing the risk of accumulation and toxicity. Dose
reduction is often necessary.
9. What is the primary determinant of a maintenance dose for a drug?
A. The drug's cost
B. Clearance and the desired steady-state concentration
C. The drug's color
D. The patient's height
3|Page
, Page 4 of 72
Rationale: Maintenance dosing is based on clearance (the rate of drug
elimination) and the target steady-state concentration.
10. Which of the following best describes the concept of a loading dose?
A. A dose given only when symptoms worsen
B. An initial higher dose used to rapidly achieve therapeutic drug concentrations
C. A maintenance dose given daily
D. A dose reduced for renal impairment
Rationale: Loading doses rapidly achieve therapeutic levels when the time to
steady state would otherwise be prolonged.
11. Which of the following statements about a drug with a narrow therapeutic
index is most accurate?
A. It has a wide margin of safety
B. It requires careful monitoring of serum levels to avoid toxicity
C. It never requires dose adjustment
D. It is always safe in pregnancy
Rationale: A narrow therapeutic index means the toxic and effective ranges are
close, requiring careful monitoring of drug levels (e.g., digoxin, lithium, warfarin).
12. Which of the following is an example of a drug that requires therapeutic drug
monitoring due to a narrow therapeutic index?
A. Amoxicillin
B. Digoxin
C. Acetaminophen
D. Vitamin C
Rationale: Digoxin has a narrow therapeutic index and requires serum level
monitoring to avoid toxicity.
13. Which of the following best describes the placebo effect?
A. A drug's direct pharmacologic effect
B. A therapeutic response produced by expectation or belief rather than the
4|Page
